Reference entry — NOT a sellable lane, NOT approved. The hottest emerging obesity molecule: it folds the CagriSema idea (GLP-1 + amylin) into one molecule, in both oral and injectable forms. Investigational; racing into Phase 3. No dosing published here.
Amycretin is Novo Nordisk's first-in-class unimolecular GLP-1 + amylin agonist — the CagriSema concept in a single molecule, developed as both a pill and a weekly injection. Early-phase data are striking (~24% weight loss subcutaneously at 36 weeks; ~13% with the oral form at just 12 weeks, beating semaglutide at that timepoint), and Novo is taking both forms straight to Phase 3 in 2026. But it is early-stage (Phase 1b/2a) and not approved anywhere — the impressive numbers still need Phase 3 confirmation.
- Everywhere — investigational, not approved. Not available by prescription or compounding outside clinical trials. - Gray market: "research" amycretin sold online is unapproved and unregulated — unknown purity/dose (and, being early-stage, authenticity is especially doubtful). - This venture: not a sellable lane — an investigational drug.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.
Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.
We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Amycretin changes - nothing else.
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.